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scored according to the PERCIST guidelines and for acute and 
late toxicity the CTCAE version 4.0 was used. 
Results: The mean and median fu after SBRT are 12,4 months 
and 8 months respectively. Local control (LC), defined as the 
absence of progression in the treated sites was 79% and 
ranged from 97,7% in lesions < 10 cc to 50% in lesions > 50cc. 
21/24 pts are alive, 6 of them at more than 1 year from 
SBRT. The main cause of failure was the appearance of new 
lung metastases (14/24). Median OS was 8 mos. No pt 
experienced acute G3 toxicity. 4 pts presented a grade 2 
acute lung toxicity and 2 pts hemoptysis in the days following 
SBRT, which receded spontaneously in both cases. One 
patients presented a rib fracture 19 months after SBRT. 
Conclusions: SBRT is a safe and effective treatment for LM 
from sarcoma and might be used as an alternative option in 
pts unfit for surgery. Local control is related to the volume of 
the lesion (< 10 cc: LC 97,7%; > 50 cc: LC 50%). 
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Purpose/Objective: Primary intradural extramedullary Ewing 
sarcoma (PIEES) is morphologically similar to central 
primitive neuroectodermal tumors (cPNET), but is generally 
treated with Ewing sarcoma systemic therapy and focal 
radiotherapy rather than craniospinal radiotherapy, which is 
standard of care for cPNET. The goal of this report is to 
determine the patterns of failure and optimal radiotherapy 
target volumes for PIEES. 
Materials and Methods: The Mayo Clinic tumor registry was 
utilized to identify all Ewing sarcoma of the spine. Only 
patients diagnosed after 1992, when Ewing translocation 
analysis and MRI became routinely available, were included. 
A retrospective chart review was performed to identify 
intradural extramedullary tumors. A PubMed search was 
performed using combinations of the keywords Ewing 
sarcoma, intradural, extramedullary and cauda equina. Only 
reports including radiotherapy (RT) dose and target volume 
and follow-up were included in the analysis. 
Results: Tumor registry review identified 25 patients with 
Ewing sarcoma of the spine, of which 4 patients had PIEES at 
the cervical, thoracic or lumbar levels. All four patients were 
male, age 25 - 60 years old. All patients were treated with 
the Ewing chemotherapy regimen vincristine, doxorubicin, 
cyclophosphamide, ifosfamide and etoposide (VDC/IE); 
however one did not receive cyclophosphamide. Two 
patients, one with lumbar disease and the other with 
thoracic disease, were treated with focal radiation to a dose 
of 50.4 Gy. Both recurred outside of the RT volume, but 
within the craniospinal axis at 4 and 41 months after 
completing therapy, and have subsequently died. One patient 
received craniospinal RT to a total dose of 36 Gy with an 
additional 18 Gy to the primary disease, and is without 
evidence of disease 16 months from the end of therapy. The 
fourth patient is currently under treatment with a planned 30 
Gy to the craniospinal axis and 59.4 Gy to the primary 
disease. 
The literature review identified 10 case reports that met 
criteria. Tumor locations included 2 cervical, 1 thoracic to 
sacral, 4 lumbar and 3 lumbosacral. Six patients were male 
and 4 female with ages ranging from 10 - 60 years old. All 
patients received Ewing –type systemic chemotherapy and 
focal radiation, with a total dose ranging from 30 - 56 Gy. 
Four of the 10 patients experienced distant craniospinal axis 
failure, and one additional patient experienced local failure. 
Median time to recurrence was 8 months (range of 4-31 
months). Two of the 4 patients with craniospinal recurrence 
have died at 14 and 48 months from diagnosis. The patient 
with local recurrence also died 12 months after diagnosis. 
Conclusions: RT appears to provide excellent local control 
with only 1 of 14 patients experiencing local failure, 
however, 6 of 12 patients treated with focal RT experienced 
distant craniospinal axis failure. Craniospinal radiotherapy 
should be considered to improve long-term outcomes in this 
rare tumor.  
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Purpose/Objective: To show our experience, analyse 
different prognosis factor and to compare our results with 
the literature. 
Materials and Methods: Data from 40 consecutive adult 
patients, who were treated between December of 1997 and 
December of 2012, were retrospectively analysed. All of 
them underwent head frame stereotactic radiosurgery (SRS) 
with LINAC as primary, adjuvant or salvage treatment for 
glomus tumours. Tumour and clinical control was calculated 
using the Kaplan-Meier method. Bivariate statistical analyses 
were performed to examine different prognosis factor, using 
logistic regression analyses. 
Results: The median of follow-up was 71 months. The 
radiological local control and clinical control was achieved in 
37 patients (92.5%) and in 29 patients (72.5%) respectively. 
Toxicity was detected in 4 patients (10%) with new symptoms 
related to impairment of V, VIII and X cranial par. In the 
bivariate analysis, dose coverage and maximum dose were 
associated with tumor control with an OR of 5.29 (p=0.041) 
and 2.67 (p=0.056) respectively. 
Conclusions: SRS is a safe and efficacious treatment for 
glomus tumours that is associated with high probability of 
radiological and clinical control and low incidence of 
morbidity. 
